A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A Phase II clinical trial of patients undergoing a cord blood transplant plus a stem cell product derived from pooled cord blood units showed that 27 of 28 patients (96%) with leukemias and myelodysplastic syndrome survived at least one year and none of the patients experienced severe acute or chronic graft-versus-host disease, which are common complications of stem cell transplantation.
This article was originally published on MedicalXpress.com
